Neurogene develops AAV vector‑based gene therapies to deliver functional genes to patients with rare, devastating neurological diseases. Its lead programs use adeno-associated virus (AAV) vector technology, and the company is also developing novel gene therapy technologies to address challenges conventional approaches cannot. Proceeds from the recent financing will be used to advance multiple gene therapy programs into the clinic and to accelerate investment in product design and the company’s technology platform. Neurogene also plans to build out state-of-the-art AAV vector GMP manufacturing capabilities. The company works with academic researchers, patient advocacy organizations, and caregivers to bring treatments that address underlying genetic causes where no effective options currently exist. The company announced completion of a $115 million Series B financing to support these efforts. Neurogene develops AAV-based gene therapies to deliver functional genes for patients with rare neurological disorders. The company partners with academic researchers, patient advocacy organizations, and caregivers to advance therapies that address underlying genetic causes. Neurogene is also investing in novel technologies aimed at indications not well served by traditional gene therapy approaches. With a recently announced $68.5 million Series A, the company will advance multiple gene therapy programs into IND-enabling studies and clinical trials. Proceeds will also be used to establish a viral vector manufacturing facility. The company’s programs are focused on neurological diseases that currently have no effective treatment options.

Total raised

$184M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2020